As employers face multiple headwinds in managing specialty drug spend, traditional PBM models lack alignment and incentives to fully address these issues for their clients. Learn more in this insightful white paper published in JMCP and authored by our CEO Brenda Motheral.
REDUCE OFF-LABEL USE
10% of specialty drug spend is off-label
MANAGE MEDICAL SPECIALTY COSTS
Specialty spend will average $1147 PMPY across the pharmacy and medical benefits in 2020
OPTIMIZE THE SITE OF CARE
Shifting coverage to the pharmacy benefit may not be the most cost-effective option
Archimedes’ clients are seeing an average savings of more than
in specialty in the first year.
Carve out your specialty drug benefit to take back control and save money
Archimedes is helping plan sponsors address the rising cost of specialty medications through our unique specialty PBM carve out solution
- Moves management of specialty drug benefit away from traditional PBM
- Leverages Archimedes clinical expertise and technology to implement a robust prior authorization program and case management for high cost specialty patients
- Utilizes Archimedes’ formulary to optimize appropriate use and net cost before rebates
- Provides plan sponsors with the option to include management of specialty medical drugs, which make up 40% of all specialty drug spend
Like the scientist and inventor who provided the inspiration for our name, we leverage an unmatched combination of analytic expertise, technological capabilities, experience, and pragmatism to provide employers and health plans with the information that they really need to control the growing cost of traditional and specialty drugs across the pharmacy and medical benefits.
Empowering plan sponsors by providing objective analytic tools and technology-driven solutions isn’t our top concern. It’s our only concern.